Valera's Vantas Prostate Cancer Implant To Launch By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Valera is assembling a 50-rep urology sales force and building inventory for histrelin. Company hopes to distinguish Vantas from the other 12-month implant, Bayer/Alza's Viadur, based on the design of the delivery system.
You may also be interested in...
Indevus Gains Supprelin LA With Purchase Of Valera
Indevus also expects to out-license Valera's early stage pipeline, as well as several of its own products.
Indevus Gains Supprelin LA With Purchase Of Valera
Indevus also expects to out-license Valera's early stage pipeline, as well as several of its own products.
J&J Viadur Promotional Aid Omits Risk Information, FDA Warning Letter Says
A patient disc puzzle includes no risk information, FDA said. The promotion's references to Viadur's website and toll-free number do not satisfy risk disclosure requirements.